Clinical trial
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine…
NCT00130936 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00130936 |
|---|---|
| Title | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates |
| Official title | Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Esophageal Cancer, Tumors |
| Intervention type | Drug |
| Interventions | Epirubicin, Carboplatin, Capecitabine |
| Enrollment | 50 |
| Start date | Oct 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Aug 17, 2005 |
| Last update posted | Feb 15, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: